September 8, 2020 | Blog
Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?
April 14, 2020 | Blog
Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.
March 24, 2020 | Blog
The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.
March 24, 2020 | Blog
A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.
November 10, 2019 | Blog, News
The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. CBPartners’ Cell and Gene Therapy Center of Excellence explored eight promising presentations from the CAR T event.
August 17, 2019 | Blog
Eventual success of innovative payment models broadening access and realising the promise of cutting-edge, curative gene and cell therapies will depend on the ability of manufacturers and payers to compromise on risk sharing. Manufacturers of novel one-time treatments can increase the likelihood of successful negotiations by following a few guiding principles - CBPartners' Cell and Gene Therapy Center of Excellence analyse the future success of innovative payment models.
March 5, 2018 | Blog
After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. CBPartners' Cell and Gene Therapy Center of Excellence explores the challenges that CAR-T combination therapies face.
September 17, 2017 | Blog
Yet another drug pricing debate has started to brew in the USA, with its epicentre right in DC. Two Democratic members of the US House (Elijah Cummings (D-MD) and Peter Welch (D-VT)), announced that they are launching an investigation into the pricing of disease-modifying treatments for multiple sclerosis (MS). CBPartners investigates MS pricing in the political context.